Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study of C16TR for Inhalation to Determine Its Safety, Tolerability, and Pharmacokinetics With an Open-label Tyvaso® Cohort in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs Treprostinil palmitil (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions; First in man
- Sponsors Insmed
- 31 Aug 2016 According to an Insmed media release, data from this trial were accepted for presentation at the European Respiratory Society (ERS) 2016 International Congress
- 05 May 2016 Status changed from planning to completed, as reported by Insmed media release.
- 05 Mar 2015 New trial record